Literature DB >> 25430517

Adopting a Sustainable Community of Practice Model when Developing a Service to Support Patients with Epidermolysis Bullosa (EB): A Stakeholder-Centered Approach.

Rosemary Joan Gowran1, Avril Kennan, Siobhán Marshall, Irene Mulcahy, Sile Ní Mhaille, Sarah Beasley, Mark Devlin.   

Abstract

OBJECTIVES: Epidermolysis bullosa (EB) is a rare, genetic skin condition that is complicated, distressing, and painful and permeates every aspect of patients' lives. Support services are essential for meeting the primary needs of patients and families living with EB; however, provision is challenged by many complex issues. In collaboration with the patient organization DEBRA Ireland, this research conducted an in-depth analysis of Irish healthcare support services for EB, with a view to moving towards an improved and sustainable care pathway.
METHODS: A sustainable community of practice model (SCOP), as a core construct provided a simplified framework when studying this complex system. The research utilized mixed methods, comprising individual interviews, questionnaires, and a participatory action research workshop based on a soft systems approach. The study engaged patients, family members, service providers, and policy developers.
RESULTS: Findings emphasized that the complexities of life with EB are more than 'skin deep'. The lived experience of stakeholders revealed many levels of emotion, both positive and heart-rending. Despite the positive efforts of specialists in this field, inadequacies to meet the primary needs of people with EB, such as bandages-fundamental for survival-were highlighted. Participants reported challenges relating to understanding patients' needs, access to consistent services within hospitals and the community, time constraints, and the strong emotions evoked by this severe and rare disease.
CONCLUSIONS: The study identified several areas that can be targeted to bring about improvements in meeting primary needs. Education and research at public, policy, and practice levels need to be prioritized. It is imperative that citizens move beyond an awareness that EB exists and demonstrate a consciousness about the importance of advocating and enabling seamless and sustainable support services through collective action.

Entities:  

Mesh:

Year:  2015        PMID: 25430517     DOI: 10.1007/s40271-014-0097-5

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  24 in total

1.  A day in the life of a patient with DDEB.

Authors:  Michael J Dietz
Journal:  J Am Acad Dermatol       Date:  2004-07       Impact factor: 11.527

2.  Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews.

Authors:  Corinne van Scheppingen; Ant T Lettinga; José C Duipmans; Carel G B Maathuis; Marcel F Jonkman
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

3.  The psychosocial impact of epidermolysis bullosa.

Authors:  Emma Dures; Marianne Morris; Kate Gleeson; Nichola Rumsey
Journal:  Qual Health Res       Date:  2011-02-22

4.  Quality of life in epidermolysis bullosa.

Authors:  H M Horn; M J Tidman
Journal:  Clin Exp Dermatol       Date:  2002-11       Impact factor: 3.470

5.  Family burden in epidermolysis bullosa is high independent of disease type/subtype.

Authors:  Stefano Tabolli; Calogero Pagliarello; Claudia Uras; Cristina Di Pietro; Giovanna Zambruno; Daniele Castiglia; Francesca Sampogna; Damiano Abeni
Journal:  Acta Derm Venereol       Date:  2010-11       Impact factor: 4.437

6.  The experiences of young people with Epidermolysis Bullosa Simplex: a qualitative study.

Authors:  E Felicity Williams; Kenneth Gannon; Kristina Soon
Journal:  J Health Psychol       Date:  2011-03-25

7.  Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa.

Authors:  Francesco Margari; Paola A Lecce; Wanda Santamato; Patrizia Ventura; Nicola Sportelli; Giuseppina Annicchiarico; Ernesto Bonifazi
Journal:  J Clin Psychol Med Settings       Date:  2010-12

8.  Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size.

Authors:  J-D Fine; L B Johnson; M Weiner; C Suchindran
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

Review 9.  Inherited epidermolysis bullosa.

Authors:  Jo-David Fine
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

10.  Nurse-patient relationship: a dichotomy of expectations.

Authors:  Wendy Moyle
Journal:  Int J Ment Health Nurs       Date:  2003-06       Impact factor: 3.503

View more
  5 in total

1.  The imperative for patient-centred research to develop better quality services in rare diseases.

Authors:  Karen Facey; Helle Ploug Hansen
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

2.  Use of the nominal group technique to identify stakeholder priorities and inform survey development: an example with informal caregivers of people with scleroderma.

Authors:  Danielle B Rice; Mara Cañedo-Ayala; Kimberly A Turner; Stephanie T Gumuchian; Vanessa L Malcarne; Mariët Hagedoorn; Brett D Thombs
Journal:  BMJ Open       Date:  2018-03-02       Impact factor: 2.692

Review 3.  Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines.

Authors:  K Martin; S Geuens; J K Asche; R Bodan; F Browne; A Downe; N García García; G Jaega; B Kennedy; P J Mauritz; F Pérez; K Soon; V Zmazek; K M Mayre-Chilton
Journal:  Orphanet J Rare Dis       Date:  2019-06-11       Impact factor: 4.123

4.  Foot care in epidermolysis bullosa: evidence-based guideline.

Authors:  M T Khan; M O'Sullivan; B Faitli; J E Mellerio; R Fawkes; M Wood; L D Hubbard; A G Harris; L Iacobaccio; T Vlahovic; L James; L Brains; M Fitzpatrick; K Mayre-Chilton
Journal:  Br J Dermatol       Date:  2019-10-23       Impact factor: 9.302

5.  Living with epidermolysis bullosa: Daily challenges and health-care needs.

Authors:  Sandra Kearney; Ann Donohoe; Eilish McAuliffe
Journal:  Health Expect       Date:  2019-12-23       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.